全髋或全膝关节置换术后利伐沙班后阿司匹林与单用阿司匹林的比较
完整摘要 · 中文译文
背景:研究表明,在初始短期使用利伐沙班后改用阿司匹林,对于全髋或全膝关节置换术后静脉血栓栓塞的预防是安全且有效的,但单独使用阿司匹林仍存在不确定性。 方法:在这项多中心、双盲、随机、对照试验中,我们分配患者在全髋或全膝关节置换术后前5天接受每日一次的血栓预防治疗,方案为81 mg阿司匹林或10 mg口服利伐沙班。随后所有患者在膝关节置换术后额外9天、髋关节置换术后额外30天继续接受每日81 mg阿司匹林的血栓预防治疗。对患者随访90天,观察症状性静脉血栓栓塞(包括近端深静脉血栓形成或肺栓塞)(主要有效性结局)及出血并发症(主要安全性结局)。单独使用阿司匹林相较于利伐沙班-阿司匹林的非劣效界值为0.7个百分点。 结果:共有5429例患者接受了随机分组。单用阿司匹林组2718例患者中有13例(0.48%)发生静脉血栓栓塞,利伐沙班-阿司匹林组2647例患者中有12例(0.45%)发生静脉血栓栓塞(风险差异,0.02个百分点;95%置信区间[CI],-0.34至0.39;非劣效性P<0.001)。单用阿司匹林组2718例患者中有45例(1.66%)发生大出血或临床相关非大出血事件,利伐沙班-阿司匹林组2647例患者中有54例(2.04%)发生此类事件(风险差异,-0.38%;95%CI,-1.11至0.34)。 结论:在全髋关节和全膝关节置换术后,单用阿司匹林在预防症状性静脉血栓栓塞方面不劣于先使用利伐沙班后使用阿司匹林的策略,且出血事件无临床相关差异。(由加拿大卫生研究院资助;EPCAT III ClinicalTrials.gov注册号,NCT04075240。)
完整摘要 · 英文原文
BACKGROUND: Aspirin after an initial short course of rivaroxaban has been shown to be safe and effective for the prevention of venous thromboembolism after total hip or total knee arthroplasty, but uncertainty remains about the use of aspirin alone. METHODS: In this multicenter, double-blind, randomized, controlled trial, we assigned patients to receive once-daily thromboprophylaxis with either 81 mg of aspirin or 10 mg of oral rivaroxaban for the first 5 days after total hip or total knee arthroplasty. All the patients then received further thromboprophylaxis with 81 mg of aspirin daily for 9 additional days after knee arthroplasty and for 30 additional days after hip arthroplasty. Patients were followed for 90 days for symptomatic venous thromboembolism, which consisted of either proximal deep-vein thrombosis or pulmonary embolism (primary effectiveness outcome), and for bleeding complications (primary safety outcome). The noninferiority margin for aspirin alone as compared with rivaroxaban-aspirin was 0.7 percentage points. RESULTS: A total of 5429 patients underwent randomization. Venous thromboembolism developed in 13 of 2718 patients (0.48%) in the aspirin-alone group and in 12 of 2647 patients (0.45%) in the rivaroxaban-aspirin group (risk difference, 0.02 percentage points; 95% confidence interval [CI], -0.34 to 0.39; P<0.001 for noninferiority). Major bleeding or clinically relevant nonmajor bleeding events occurred in 45 of 2718 patients (1.66%) in the aspirin-alone group and in 54 of 2647 patients (2.04%) in the rivaroxaban-aspirin group (risk difference, -0.38%; 95% CI, -1.11 to 0.34). CONCLUSIONS: After total hip and total knee arthroplasty, the use of aspirin alone was not inferior to a strategy of using rivaroxaban followed by aspirin for the prevention of symptomatic venous thromboembolism, with no clinically relevant difference in bleeding events. (Funded by the Canadian Institutes of Health Research; EPCAT III ClinicalTrials.gov number, NCT04075240.).